Human Testis-Derived Pluripotent Stem Cell Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a reliable method to generate human adult pluripotent stem cells that can be used in clinical applications, such as stem cell therapies, without the ethical concerns associated with interventions in human embryos, as existing methods using mouse pluripotent stem cells are limited in their clinical applications due to significant differences between mouse and human stem cells.
Innovation Solution
A method involving the isolation of cells from human testicular parenchyma, cultivation in the presence of stem cell growth factors, selection based on specific surface markers, and subsequent purification using collagen and laminin, followed by cultivation with leukemia inhibitory factor to obtain pluripotent stem cells, which are then characterized by their ability to form teratomas and differentiate into all three germ layers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mouse pluripotent stem cells are used, then stem cell generation is achieved, but clinical applicability is limited due to species differences
Solution Approach 1:
The patent changes the source parameter from mouse testicular cells to human testicular cells, and modifies culture conditions (growth factors, matrix proteins, LIF) to generate human pluripotent stem cells that are clinically applicable while maintaining the stem cell generation process
2Reliability
If human embryonic stem cells are used, then pluripotency is achieved, but ethical concerns arise from embryo intervention
Solution Approach 1:
The patent uses an intermediary approach by deriving pluripotent stem cells from adult human testicular tissue rather than embryos, employing specific culture mediators (GDNF, laminin, LIF) to achieve pluripotency without ethical concerns associated with embryo destruction
3Manufacturing precision
If multiple cell selection steps are performed, then cell purity is improved, but process complexity increases
Solution Approach 1:
The patent segments the cell selection process into distinct sequential steps: first selecting CD49f+ cells from testicular tissue, then isolating laminin-binding cells from the first selection, allowing systematic purification while maintaining process organization and control
Data Source
AI summary
The present invention relates to a method for generating pluripotent stem cells and to pluripotent stem cells generated from human testis.